Control Bionics Ltd. (CBL) AI Stock Analysis

• Market Cap: AU$12.02M
• Dividend Yield: N/A
• Average Volume (3M): 81.52K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.71
• Revenue Growth: 14.84%
• EPS Growth: 39.64%
• Country: AU
• Employees: 25
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.01
• Shares Outstanding: 353,533,330
• 10 Day Avg. Volume: 125,245
• 30 Day Avg. Volume: 81,521
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 44 Neutral
• Price Target: AU$0.00 ▼(-100.00% Downside)

Control Bionics Ltd. is experiencing financial struggles due to declining revenues and consistent losses, reflected in the low financial performance score. Technical analysis offers a mixed view with near-term bullish momentum but also overbought conditions. The valuation is unattractive with a negative P/E ratio and no dividend yield. These factors collectively result in a below-average stock score.

Control Bionics Ltd. Business Overview & Revenue Model

Company Description

Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia and North America. The company offers NeuroNode Trilogy and NeuroNode3 systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. It also provides Cosmos Connect, a device to control a range of devices, including wheelchairs, dining robots, and gaming systems; Uno Touch, a speech generating device; and other sensors for multiple applications. The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020. Control Bionics Limited was incorporated in 2005 and is based in Camberwell, Australia.

How the Company Makes Money

Control Bionics Ltd. makes money primarily through the sale of its assistive communication devices and related accessories. The company generates revenue by marketing its products directly to consumers, healthcare institutions, and through distribution partnerships. Key revenue streams include the NeuroNode technology, which combines brain-computer interface and electromyography to allow users to control devices with minimal muscle movement. The company may also engage in partnerships with healthcare providers and institutions for product trials and adoption, further contributing to its earnings.

Control Bionics Ltd. Financial Statement Overview

Summary

Control Bionics Ltd. is facing financial difficulties with declining revenues and continued losses. The balance sheet remains stable with low debt levels, but the negative cash flow highlights liquidity concerns. The company must focus on improving operational efficiencies and cash management to enhance financial stability.

Income Statement

Control Bionics Ltd. shows a declining revenue trend with a decrease from $5.4M in 2023 to $5.1M in 2024. The company is operating at a loss with a negative net profit margin of -115.3% in 2024, indicating high expenses relative to revenue. EBITDA and EBIT margins are also negative, reflecting operational inefficiencies.

Balance Sheet

The balance sheet reflects a moderate Debt-to-Equity Ratio of 0.15 in 2024, suggesting low leverage. However, the Return on Equity is negative due to net losses, and the Equity Ratio is 69.4%, indicating a stable equity base but limited profitability.

Cash Flow

Free cash flow is negative, showing a worsening cash position with a Free Cash Flow of -$5.4M in 2024. The operating cash flow to net income ratio is slightly below 1, indicating challenges in converting sales into cash.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.35M	5.64M	4.50M	4.09M	3.10M
Gross Profit	3.90M	3.71M	-2.91M	2.50M	215.51K
EBITDA	-5.01M	-5.14M	-5.58M	-3.40M	-989.96K
Net Income	-5.91M	-5.63M	-6.11M	-3.55M	-1.01M
Balance Sheet
Total Assets	9.03M	8.70M	13.44M	18.35M	20.51M
Cash, Cash Equivalents and Short-Term Investments	980.76K	935.50K	5.21M	12.33M	1.43M
Total Debt	961.74K	128.50K	284.82K	14.87K	46.00K
Total Liabilities	2.76M	1.55M	1.51M	1.19M	387.00K
Stockholders Equity	6.27M	7.15M	11.92M	17.16M	20.13M
Cash Flow
Free Cash Flow	-5.38M	-4.98M	-5.75M	-4.04M	-1.17M
Operating Cash Flow	-4.91M	-4.53M	-5.60M	-3.99M	-864.05K
Investing Cash Flow	-473.09K	-457.54K	-147.74K	-53.40K	-301.85K
Financing Cash Flow	5.43M	706.43K	-87.33K	14.92M	1.79M

Control Bionics Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.03
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CBL, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.04, and below the 200-day MA of 0.04, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 31.86 is Neutral, neither overbought nor oversold. The STOCH value of -56.51 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CBL.

Control Bionics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AT1	50 Neutral	AU$21.06M	-3.38	―	―	-7.20%	28.70%
ADR	47 Neutral	AU$7.45M	-0.91	―	―	-2.82%	52.38%
UCM	46 Neutral	AU$3.12M	-0.91	―	―	-30.80%	-38.95%
HMD	45 Neutral	AU$44.77M	-8.27	―	―	-34.06%	75.47%
CBL	44 Neutral	AU$12.02M	―	-103.74%	―	14.84%	39.64%
IRX	38 Underperform	AU$5.98M	-4.52	―	―	―	-55.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Control Bionics Ltd. Corporate Events

Control Bionics Achieves Record Year with Strategic Market Expansion

Control Bionics Limited reported a record year with a 15% increase in sales revenue, driven by strong growth in the US due to the adoption of the HCPCS code and successful distribution strategies. The company is advancing its NeuroNode and NeuroStrip technologies across multiple markets, with significant interest from distributors in the US and Europe. The Australian market also showed a 20% revenue increase, and strategic partnerships are being pursued to enhance distribution. The company’s focus on innovation and strategic market expansion is positioning it for continued growth.

Control Bionics to Host Investor Webinar on Quarterly Results

Control Bionics Limited announced an upcoming investor webinar to discuss its quarterly results, with CEO Jeremy Steele presenting and answering questions. This event highlights the company’s ongoing efforts to engage stakeholders and provide transparency about its financial performance and strategic direction.

Control Bionics Limited Announces Cessation of Securities

Control Bionics Limited announced the cessation of 967,720 securities due to the expiry of options or other convertible securities without exercise or conversion as of February 28, 2025. This announcement may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and market positioning.